Status:
COMPLETED
Measuring Active Microglia in Progressive Multiple Sclerosis
Lead Sponsor:
Weill Medical College of Cornell University
Collaborating Sponsors:
Genzyme, a Sanofi Company
Conditions:
Secondary Progressive Multiple Sclerosis
Eligibility:
All Genders
18-80 years
Brief Summary
This is pilot study designed to quantifying the innate immune inflammatory burden in a cohort of secondary progressive multiple sclerosis subjects. Innate immunity is recognized as a major cause of ti...
Detailed Description
This is pilot study designed to determine the baseline and longitudinal regional-specific change in uptake of \[11C\]PK-11195 in subjects with secondary progressive multiple sclerosis (SPMS). Eighteen...
Eligibility Criteria
Inclusion
- Subjects age 18-80
- Secondary progressive MS subjects either untreated or on consistent treatment for six-months prior to enrollment
- Norman Controls
Exclusion
- Subjects pregnant or woman of child-bearing age not utilizing effective birth control
- Primary progressive MS subjects
- Relapsing remitting MS subjects
- Unstable SPMS subject for which treatment change within the 24 months is likely
- Age-Healthy controls will be excluded if have any of the following medical conditions:
- Any central nervous system disorder
- Any systemic auto-immune disorder
- Pregnant or woman of child-bearing age not utilizing effective birth control
- Subjects will be withdrawn from the study if treatment is changed during the 24-month study
Key Trial Info
Start Date :
July 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2020
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT02207075
Start Date
July 1 2014
End Date
December 1 2020
Last Update
January 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Weill Cornell Medical College
New York, New York, United States, 10021